AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan
18 April 2022 - 2:03PM
Amoy Diagnostics Co., Ltd (AmoyDx), a China based innovative
molecular diagnostics company (SZSE: 300685), today announces that
it has entered into a Master Collaboration Agreement (Agreement)
with AstraZeneca (LSE/STO/Nasdaq: AZN), a global, science-led
biopharmaceutical company. The master collaboration agreement
enables the Parties to collaborate in the development and
commercialization of AmoyDx assays that may cover any type of
indication or biomarker for companion diagnostic (CDx) use with
AstraZeneca medicines globally.
The first projects to be initiated under the
Agreement include the co-development of a CDx to identify prostate
cancer patients with Homologous Recombination Repair (HRR) gene
mutations in China, the EU and Japan, and a CDx to identify breast
cancer patients with BRCA gene mutations in the EU for Lynparza®
(olaparib) monotherapy. HRR and BRCA mutations are well-documented
targets for PARP inhibitor treatment and are important biomarkers
that can inform potential treatment options including a PARP
inhibitor. Lynparza® (olaparib) is a first-in-class PARP inhibitor
jointly developed by AstraZeneca and MSD and approved in a number
of countries for the treatment of advanced ovarian, breast,
prostate and pancreatic cancers. The AmoyDx decentralized CDx are
based on the HANDLE® system, a proprietary NGS library construction
technology developed by AmoyDx, that can enable the testing of HRR
or BRCA gene mutations to be completed within three days.
Li-Mou Zheng, Ph.D., Founder and Chairman of
AmoyDx, commented: “We are very pleased to announce today that we
are further developing our partnership with AstraZeneca by entering
into a master collaboration agreement. AmoyDx is a trustworthy CDx
co-development partner with rich expertise in R&D, Regulatory
Affairs and Commercialization globally. AmoyDx and AstraZeneca
share the common core value of prioritizing patients, and we will
work together to accelerate the contribution for the benefit of
patients.”
About Amoy Diagnostics Co.,
Ltd.Amoy Diagnostics Co., Ltd. (SZSE: 300685) is
a leading biotech company which pioneered the development and
commercialization of cancer diagnostics in China. It is the
largest provider of molecular diagnostics products for personalized
healthcare in China, as well as a service center for oncology
biomarker analysis. AmoyDx has a market-leading portfolio of
molecular tests and is the therapy diagnostics partner for several
major multinational pharmaceutical companies offering precision
therapies for cancer.
Contact:Paul Huang Director,
International businessTel: + 86-592-6806058paulhuang@amoydx.com
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024